Search research articles
Contact Us
Filters
Showing results (141-150 of 165) with videos related to
Page
of 17
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
April 17, 2018
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, et al.
BMC Cancer
|
April 2, 2021
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2021
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study
Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
Jun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial
Ryota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
Chest
|
June 6, 2022
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting
Yuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 24, 2018
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy
Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 5, 2022
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study
Mihoko Imaji, Daichi Fujimoto, Yuki Sato, et al.
Journal for Immunotherapy of Cancer
|
February 19, 2020
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)
Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 165) with videos related to
Sort By:
Page
of 17
Lung Cancer (Amsterdam, Netherlands)
|
April 17, 2018
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, et al.
BMC Cancer
|
April 2, 2021
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2021
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study
Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
Jun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial
Ryota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
Chest
|
June 6, 2022
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting
Yuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 24, 2018
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy
Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 5, 2022
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study
Mihoko Imaji, Daichi Fujimoto, Yuki Sato, et al.
Journal for Immunotherapy of Cancer
|
February 19, 2020
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)
Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita, et al.
Page
of 17